OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Mayer on Imlunestrant in HR+/HER2-Negative Advanced Breast Cancer Following Prior Endocrine Therapy

June 10th 2025

Erica L. Mayer, MD, MPH, discusses the use of imlunestrant in HR+, HER2-negative advanced breast cancer following prior endocrine therapy.

Dr Kalinsky on the Importance of Biomarker Testing in HR+/HER2-Negative Advanced Breast Cancer

June 10th 2025

Kevin Kalinsky, MD, discusses the importance of biomarker testing in guiding therapeutic decision-making in HR-positive, HER2-negative breast cancer.

Dr Kalinsky on Efficacy Data From SERENA-6 in ER+/HER2– Advanced Breast Cancer

June 10th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses data with camizestrant plus a CDK4/6 inhibitor in ER–positive, HER2-negative advanced breast cancer.

Dr Wermke on the Efficacy and Safety of Obrixtamig With Topotecan in Advanced SCLC

June 9th 2025

Martin Wermke, MD, discusses obrixtamig in combination with topotecan for the treatment of patients with advanced small cell lung cancer.

Dr Schmidt on the Role of Minimally Invasive and Robotic Modalities in Bladder Cancer

June 9th 2025

Bogdana Schmidt, MD, MPH, discusses the role of minimally invasive and robotic strategies for the treatment of patients with bladder cancer.

Dr Rugo on QOL Data From SERENA-6 in ER+/HER2– Advanced Breast Cancer

June 9th 2025

Hope S. Rugo, MD, discusses quality of life data from the phase 3 SERENA-6 study.

Dr Luke on the Role of IMA203 in Previously Treated Advanced Cutaneous Melanoma

June 6th 2025

Jason Luke, MD, discusses IMA203 vs investigator’s choice of standard therapy in patients with previously treated advanced cutaneous melanoma.

Dr Rugo on Research Needed to Clarify the Role of T-DXd Plus Pertuzumab in HER2+ Breast Cancer

June 6th 2025

Hope Rugo, MD, discusses the application of findings from the DESTINY-Breast09 trial of T-DXd plus pertuzumab in HER2-positive breast cancer.

Dr Rugo on Ongoing ADC Investigations Set to Shift Practice in HER2+ Breast Cancer

June 6th 2025

Hope Rugo, MD, discusses the evolving use of antibody-drug conjugates in HER2-positive breast cancer.

Dr Mayer on ESR1 Testing Methods in the SERENA-6 Study of Patients With ER+/HER2– Advanced Breast Cancer

June 5th 2025

Erica L. Mayer, MD, MPH, discusses ESR1 mutation detection by ctDNA liquid biopsy in the phase 3 SERENA-6 study.

Dr Tolaney on the Clinical Implications of First-Line T-DXd Plus Pertuzumab in HER2+ Breast Cancer

June 5th 2025

Sara M. Tolaney, MD, MPH, details the clinical implications for first-line T-DXd/pertuzumab for the treatment of patients with HER2-positive breast cancer.

Dr Sammons on the Significance of DESTINY-Breast09 for the HER2+ Breast Cancer Treatment Paradigm

June 5th 2025

Sarah Sammons, MD, contextualizes the importance of T-DXd plus pertuzumab within the evolving ADC arsenal for HER2-positive breast cancer.

Dr Haas on 5-Year Outcomes With Adjuvant Pembrolizumab in ccRCC

June 5th 2025

Naomi B. Haas, MD, shares 5-year follow-up data with adjuvant pembrolizumab in patients with clear cell renal cell carcinoma.

Dr O’Meara on the Evolving Role of ADCs in HER2+ Breast Cancer

June 4th 2025

Tess O’Meara, MD, highlights the role of antibody-drug conjugates for the treatment of patients with HER2-positive breast cancer.

Dr Saad on the FDA Approval of Darolutamide in mCSPC

June 4th 2025

Fred Saad, MD, discusses the FDA’s approval of darolutamide without chemotherapy for metastatic castration-sensitive prostate cancer

Dr Preeshagul on Emerging Treatments in SCLC

June 3rd 2025

Isabel Preeshagul, DO, MBS, highlights the role of emerging therapies in the SCLC landscape, including tarlatamab and durvalumab.

Dr Rathkopf on the Efficacy of Niraparib Plus Abiraterone Acetate/Prednisone in HRR-Altered mCSPC

June 3rd 2025

Dana E. Rathkopf, MD, discusses the efficacy of niraparib plus abiraterone acetate and prednisone in patients with mCSPC and HRR gene alterations.

Dr In on the Safety and Efficacy of RP1 in Patients With Melanoma Post–PD-1 Inhibitor Progression

June 2nd 2025

Gino Kim In, MD, shares findings from a subgroup analysis of RP1 efficacy in injected and non-injected melanoma lesions after PD-1 inhibitor progression.

Dr Tolaney on the PFS Benefit With First-Line T-DXd Plus Pertuzumab in HER2+ Breast Cancer

June 2nd 2025

Sara M. Tolaney, MD, MPH, shares interim efficacy results from the DESTINY-Breast09 study of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.

Dr Olawaiye on Data for Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

June 2nd 2025

Alexander Olawaiye, MD, discusses the efficacy and safety of relacorilant plus nab-Paclitaxel in platinum-resistant ovarian cancer.